CA2484459A1 - Anti cd44 antibodies for eradicating stem cells - Google Patents

Anti cd44 antibodies for eradicating stem cells Download PDF

Info

Publication number
CA2484459A1
CA2484459A1 CA002484459A CA2484459A CA2484459A1 CA 2484459 A1 CA2484459 A1 CA 2484459A1 CA 002484459 A CA002484459 A CA 002484459A CA 2484459 A CA2484459 A CA 2484459A CA 2484459 A1 CA2484459 A1 CA 2484459A1
Authority
CA
Canada
Prior art keywords
antibody
use according
stem cells
fab
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002484459A
Other languages
English (en)
French (fr)
Inventor
Florence Smadja
John Dick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484459A1 publication Critical patent/CA2484459A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002484459A 2003-11-19 2004-10-12 Anti cd44 antibodies for eradicating stem cells Abandoned CA2484459A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873.1 2003-11-19
EP03292873A EP1532984A1 (en) 2003-11-19 2003-11-19 Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia

Publications (1)

Publication Number Publication Date
CA2484459A1 true CA2484459A1 (en) 2005-05-19

Family

ID=34429570

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002484459A Abandoned CA2484459A1 (en) 2003-11-19 2004-10-12 Anti cd44 antibodies for eradicating stem cells
CA002546566A Abandoned CA2546566A1 (en) 2003-11-19 2004-11-19 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002546566A Abandoned CA2546566A1 (en) 2003-11-19 2004-11-19 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia

Country Status (10)

Country Link
US (4) US20050147606A1 (enExample)
EP (3) EP1532984A1 (enExample)
JP (1) JP2007513610A (enExample)
KR (1) KR20060126659A (enExample)
CN (1) CN1898268A (enExample)
AT (1) ATE480565T1 (enExample)
AU (1) AU2004290918B2 (enExample)
CA (2) CA2484459A1 (enExample)
DE (1) DE602004029078D1 (enExample)
WO (1) WO2005049082A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP2783700A1 (en) * 2006-09-07 2014-10-01 Stemline Therapeutics, Inc. Cancer stem cell-targeted cancer therapy
EP2526970A1 (en) * 2006-09-07 2012-11-28 Stemline Therapeutics, Inc. Monitoring cancer stem cells
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (en) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
AU2010221168A1 (en) * 2009-03-06 2011-10-06 Angstrom Pharmaceuticals, Inc. Compositions and methods for modulation of cell migration
PT2531527E (pt) * 2010-02-04 2014-05-16 Hoffmann La Roche Anticorpo monoclonal contra cd44 para ser utilizado no tratamento de carcinoma de células escamosas da cabeça e do pescoço
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
SG11201401405PA (en) * 2011-10-26 2014-05-29 Univ California Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies
WO2014201417A1 (en) * 2013-06-14 2014-12-18 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
WO2019084240A1 (en) * 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF TREATING CANCER USING RADIO-labeled CD45 ANTI-CD45 IMMUNOGLOBULIN AND ADOPTIVE CELLULAR THERAPIES
EP4103610A1 (en) * 2020-02-13 2022-12-21 UCB Biopharma SRL Anti cd44-ctla4 bispecific antibodies
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
EP4153192B8 (en) 2020-05-19 2024-09-04 Institut Curie Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
CA3220458A1 (en) 2021-05-18 2022-11-24 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009811A1 (en) * 1992-10-30 1994-05-11 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
KR100653803B1 (ko) * 2000-01-21 2006-12-05 소니 가부시끼 가이샤 데이터 처리 시스템 및 데이터 처리 시스템에서의 데이터 처리 방법
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Industrial Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1

Also Published As

Publication number Publication date
EP1692183B1 (en) 2010-09-08
CN1898268A (zh) 2007-01-17
EP2275444A1 (en) 2011-01-19
WO2005049082A3 (en) 2005-11-10
KR20060126659A (ko) 2006-12-08
EP1692183A2 (en) 2006-08-23
DE602004029078D1 (de) 2010-10-21
CA2546566A1 (en) 2005-06-02
AU2004290918B2 (en) 2012-03-08
US20050147606A1 (en) 2005-07-07
WO2005049082A2 (en) 2005-06-02
US20070237761A1 (en) 2007-10-11
US20070184051A1 (en) 2007-08-09
EP1532984A1 (en) 2005-05-25
ATE480565T1 (de) 2010-09-15
US20100040540A1 (en) 2010-02-18
AU2004290918A1 (en) 2005-06-02
JP2007513610A (ja) 2007-05-31

Similar Documents

Publication Publication Date Title
US20100040540A1 (en) Anti cd44 antibodies for eradicating leukaemic stem cells and breast cancer stem cells
CN101658672B (zh) 用iii类抗cea单克隆抗体和治疗剂进行联合治疗
EP4501363A1 (en) B7h4 antibody-drug conjugate and use thereof
EP3178484B1 (en) Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
KR20190069493A (ko) 항-edb 항체 및 항체-약물 접합체
JP2003505432A (ja) 抗ｅｐ−ｃａｍ抗体と化学療法剤との組合せ
CN117159703B (zh) 含抗lag-3抗体的药物组合物及其用途
US11498946B2 (en) Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients
US20150030534A1 (en) Antibody cocktails for breast cancer radioimmunotherapy
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2024183643A1 (zh) 含抗tim-3抗体的药物组合
AU2013334583B2 (en) JAM-C antibodies and methods for treatment of cancer
EP4494654A1 (en) Pharmaceutical composition of anti-tim-3 antibody and hypomethylating agent
AU2024298986C1 (en) Pharmaceutical composition containing anti-nectin4 antibody-drug conjugate and anti-pd-1 antibody and use thereof
US20260116978A1 (en) Methods of Performing Boron Neutron Capture Therapy (BNCT) in Combination with Immune Checkpoint Inhibitors to Enhance BNCT and the Anti-tumor effects of Immune Check Point Inhibitors as well as the Abscopal Effect Induced by Radiation Therapy and Methods Thereof
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用
JP2026513335A (ja) 抗ｂｔｌａを併用療法として固形腫瘍を治療する組み合わせ及び方法
HK40118654A (en) B7h4 antibody-drug conjugate and use thereof
WO2025124463A1 (zh) 抗her2的双特异性抗体及其应用
WO2023198060A1 (zh) 蛋白酶体抑制剂与抗pd-1抗体的药物组合
TW202529816A (zh) 癌症的抗體藥物偶聯物療法
CN118767126A (zh) 抗cd47抗体和阿扎胞苷联合治疗血液肿瘤
HK40102408A (zh) 含抗lag-3抗体的药物组合物及其用途
HK40102408B (zh) 含抗lag-3抗体的药物组合物及其用途
WO2023051674A1 (zh) 联合治疗血液肿瘤的抗cd47抗体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130215